Redx Oncology Ltd is a subsidiary of Redx Pharma Ltd, a UK-based company developing new drug candidates using the broad-based potential of its innovative Redox Switch™ platform.
The novel and broadly validated Redox Switch™ approach allows Redx Oncology to progress new drug development programs with lower risk and greater speed to clinical trials.
Liverpool, UK and Montreal, Canada - The early stage drug development company Redx Pharma has today reached an agreement with Canadian-based Pharmascience Inc. to licence its promising anti-cancer program which helps the immune system to recognise and fight cancer.
The program is focused on small molecules that inhibit a receptor in the body called CSF-1R or cFMS which plays an important role in the immune response to cancer.
The receptor influences the way that the body's immune system interacts with cancer cells in tumours. It also affects how quickly cancer spreads to other parts of the body, particularly to bones.
The license agreement allows Liverpool-based Redx to pursue research and development and commercialization of the Pharmascience program in oncology. The program is currently at the lead optimization stage.
